Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients

Diagnostic Microbiology and Infectious Disease

Volumn 62, Issue 4, 2008, Pages 402-406

  Jeon, Min Hyok ^a   Choi, Sang Ho ^b,c   Kwak, Yee Gyung ^b,c   Chung, Jin Won ^b,c   Lee, Sang Oh ^b,c   Jeong, Jin Yong ^b,c   Woo, Jun Hee ^b,c   Kim, Yang Soo ^b,c  

^a Soonchunhyang University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c University of Ulsan   (South Korea)

Author keywords

Carbapenem; Escherichia coli; Resistance

Indexed keywords

AMIKACIN; CARBAPENEM; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; METRONIDAZOLE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BILIARY TRACT DRAINAGE; CLINICAL EVALUATION; CONTROLLED STUDY; ENTEROBACTER INFECTION; ESCHERICHIA COLI; FEMALE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; ISOLATION PROCEDURE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 56049124344     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.08.014     Document Type: Article

References (27)

1. CDC NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32 (2004) 470-485
2. Bratu S., Brooks S., Burney S., Kochar S., Gupta J., Landman D., and Quale J. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin. Infect. Dis. 44 (2007) 972-975
3. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic. Dis. 40 (1987) 373-383
4. Charlson M., Szatrowski T.P., Peterson J., and Gold J. Validation of a combined comorbidity index. J. Clin. Epidemiol. 47 (1994) 1245-1251
5. Edmond M.B., Ober J.F., Weinbaum D.L., Pfaller M.A., Hwang T., Sanford M.D., and Wenzel R.P. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin. Infect. Dis. 20 (1995) 1126-1133
6. Gaynes R.P., and Culver D.H. Resistance to imipenem among selected gram-negative bacilli in the United States. Infect. Control. Hosp. Epidemiol. 13 (1992) 10-14
7. Gulmez D., Woodford N., Palepou M.F., Mushtaq S., Metan G., Yakupogullari Y., Kocagoz S., Uzun O., Hascelik G., and Livermore D.M. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int. J. Antimicrob. Agents 31 (2008) 523-526
8. Harris A.D., Karchmer T.B., Carmeli Y., and Samore M.H. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin. Infect. Dis. 32 (2001) 1055-1061
9. Harris A.D., Perencevich E., Roghmann M.C., Morris G., Kaye K.S., and Johnson J.A. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob. Agents Chemother. 46 (2002) 854-858
10. Harris A.D., Samore M.H., Lipsitch M., Kaye K.S., Perencevich E., and Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin. Infect. Dis. 34 (2002) 1558-1563
11. Harris A.D., Smith D., Johnson J.A., Bradham D.D., and Roghmann M.C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin. Infect. Dis. 34 (2002) 340-345
12. Hong T., Moland E.S., Abdalhamid B., Hanson N.D., Wang J., Sloan C., Fabian D., Farajallah A., Levine J., and Thomson K.S. Escherichia coli: development of carbapenem resistance during therapy. Clin. Infect. Dis. 40 (2005) e84-e86
13. Kwak Y.G., Choi S.H., Choo E.J., Chung J.W., Jeong J.Y., Kim N.J., Woo J.H., Ryu J., and Kim Y.S. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb. Drug. Resist. 11 (2005) 165-169
14. Lee S.-O., Kim N.J., Choi S.-H., Hyong Kim T., Chung J.-W., Woo J.-H., Ryu J., and Kim Y.S. Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob. Agents Chemother. 48 (2004) 224-228
15. Lucas G.M., Lechtzin N., Puryear D.W., Yau L.L., Flexner C.W., and Moore R.D. Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes. Clin. Infect. Dis. 26 (1998) 1127-1133
16. Miriagou V., Tzelepi E., Gianneli D., and Tzouvelekis L.S. Escherichia coli with a self-transferable, multiresistant plasmid coding for metallo-beta-lactamase VIM-1. Antimicrob. Agents Chemother. 47 (2003) 395-397
17. Moloughney J.G., Thomas J.D., and Toney J.H. Novel IMP-1 metallo-[beta]-lactamase inhibitors can reverse meropenem resistance in Escherichia coli expressing IMP-1. FEMS Microbiol. Lett. 243 (2005) 65-71
18. Navon-Venezia S., Chmelnitsky I., Leavitt A., Schwaber M.J., Schwartz D., and Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob. Agents Chemother. 50 (2006) 3098-4101
19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement (2004), M100-S14, NCCLS, Wayne, PA
20. Poirel L., Heritier C., Spicq C., and Nordmann P. In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J. Clin. Microbiol. 42 (2004) 3831-3833
21. Stapleton P.D., Shannon K.P., and French G.L. Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein. Antimicrob. Agents Chemother. 43 (1999) 1206-1210
22. Troillet N., Samore M.H., and Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin. Infect. Dis. 25 (1997) 1094-1098
23. Urban C., Bradford P.A., Tuckman M., Segal-Maurer S., Wehbeh W., Grenner L., Colon-Urban R., Mariano N., and Rahal J.J. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin. Infect. Dis. 46 (2008) e127-e130
24. van der Waaij D., Berghuis-de Vries J.M., and Lekkerkerk L.-v. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J. Hyg. (Lond). 69 (1971) 405-411
25. Wells C.L., Maddaus M.A., Reynolds C.M., Jechorek R.P., and Simmons R.L. Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria. Infect. Immun. 55 (1987) 2689-2694
26. Wells C.L., Jechorek R.P., Maddaus M.A., and Simmons R.L. Effects of clindamycin and metronidazole on the intestinal colonization and translocation of enterococci in mice. Antimicrob. Agents. Chemother. 32 (1988) 1769-1775
27. Wells C.L., Maddaus M.A., Jechorek R.P., and Simmons R.L. Role of intestinal anaerobic bacteria in colonization resistance. Eur. J. Clin. Microbiol. Infect. Dis. 7 (1988) 107-113